Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes.
Daiichi Sankyo Inc is developing rivoglitazone, an insulin sensitizer with peroxisome proliferator-activated receptor gamma agonistic activity, for the potential treatment of type 2 diabetes. By March 2006, phase I/III clinical trials were underway in the US and the EU.
Schimke
Katrin
K
University of Western Australia, School of Medicine and Pharmacology, Fremantle Hospital, PO Box 480, Fremantle, WA 6959, Australia. kschimke@meddent.uwa.edu.au
Davis
Timothy M E
TM
D000284:Administration, Oral; D000818:Animals; D017326:Clinical Trials, Phase III as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004341:Drug Evaluation / Q000379:methods*; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D015394:Molecular Structure; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; C521549:rivoglitazone